# Icosapent ethyl

Drug · id `cardio:icosapent-ethyl` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Vascepa

Browse, condition area: Risk and prevention; Coronary and vascular disease  

## In plain language

A prescription medicine, sold as Vascepa, that is an ethyl ester of eicosapentaenoic acid (EPA), an omega-3 fatty acid. The US label lists it for lowering very high triglycerides in adults, and, added to a statin, for lowering the risk of heart attack, stroke and some other events in adults with raised triglycerides and either established cardiovascular disease or diabetes plus other risk factors. The label warns of a higher risk of atrial fibrillation or atrial flutter needing hospital care, and of bleeding.

## Technical summary

RxNorm ingredient 1304974. NDA202057, with an original submission dated 2012-07-26 in the openFDA record. The evidence recorded here is the Amarin label and the FDA record only; this record reads no outcome trial.

## Claims, with the population each applies to

## Context: Adults with raised triglycerides, as the US Vascepa label describes them

Recipient: Adult; Population: Adult patients named in the indications of the US label for Vascepa: adults with elevated triglycerides and established cardiovascular disease or diabetes plus other risk factors, and adults with severe hypertriglyceridemia.; Care setting: Prescription medicine; the label adds the medicine to statin treatment or to diet, as stated in the indications; Geography: United States (FDA label); Life stage: Adults; the label states adult patients; Follow-up: Not applicable (label text and a regulatory record)

### The openFDA Drugs@FDA record for NDA202057 lists Vascepa, from AMARIN PHARMS, with an original submission (ORIG 1) in status AP (approved) dated 26 July 2012.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Adult patients named in the indications of the US label for Vascepa: adults with elevated triglycerides and established cardiovascular disease or diabetes plus other risk factors, and adults with severe hypertriglyceridemia.; Care setting: Prescription medicine; the label adds the medicine to statin treatment or to diet, as stated in the indications; Geography: United States (FDA label); Life stage: Adults; the label states adult patients; Follow-up: Not applicable (label text and a regulatory record)
- Limitations: An openFDA record, which openFDA says is unvalidated. It gives dates as compact numbers and does not state the indication approved in 2012; the label indications above are the current ones.
- Last checked: 2026-10-30
- Sources:
  1. Supports: FDA New Drug Application NDA202057: Vascepa (openFDA drugsfda record) (Regulator, edition The openFDA drugsfda record for application NDA202057 returned on 2026-10-30. It writes dates as compact numbers (YYYYMMDD).) <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202057>
     Locator: results\[0\].submissions\[16\]. Retrieved 2026-10-30T19:20:11Z. Source state: Current. Version fingerprint: 41292867e3d790ed006a0ecfafa198151a08bf8d01aee67bc6385f643593a81f.
     How it applies: Original submission in the FDA record.
  2. Supports: FDA New Drug Application NDA202057: Vascepa (openFDA drugsfda record) (Regulator, edition The openFDA drugsfda record for application NDA202057 returned on 2026-10-30. It writes dates as compact numbers (YYYYMMDD).) <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202057>
     Locator: results\[0\].sponsor\_name. Retrieved 2026-10-30T19:20:11Z. Source state: Current. Version fingerprint: 41292867e3d790ed006a0ecfafa198151a08bf8d01aee67bc6385f643593a81f.
     How it applies: Applicant name in the FDA record.

### The US Vascepa label says Vascepa (icosapent ethyl) is indicated, as an add-on to statin treatment at the highest dose the patient can tolerate, to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride levels (150 mg/dL or higher) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease. It is also indicated, as an adjunct to diet, to reduce triglyceride levels in adult patients with severe (500 mg/dL or higher) hypertriglyceridemia. The label says the effect on the risk of pancreatitis in patients with severe hypertriglyceridemia has not been determined.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Adult patients named in the indications of the US label for Vascepa: adults with elevated triglycerides and established cardiovascular disease or diabetes plus other risk factors, and adults with severe hypertriglyceridemia.; Care setting: Prescription medicine; the label adds the medicine to statin treatment or to diet, as stated in the indications; Geography: United States (FDA label); Life stage: Adults; the label states adult patients; Follow-up: Not applicable (label text and a regulatory record)
- Limitations: These are indications as the label states them, in the label version dated 2026-03-23. They say what FDA has approved the medicine for, not how well it works for any person. The trial evidence behind the cardiovascular indication is not read in this atlas yet.
- Last checked: 2026-10-30
- Sources:
  1. Supports: Vascepa drug label (openFDA record, set id 9c1a2828-1583-4414-ab22-a60480e8e508) (Label, edition openFDA drug label record for the Amarin Pharma Inc. label of Vascepa, label effective 20260323, fetched 2026-10-30.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c1a2828-1583-4414-ab22-a60480e8e508>
     Locator: results\[0\].indications\_and\_usage\[0\]. Retrieved 2026-10-30T19:20:10Z. Source state: Current. Version fingerprint: 12fe4482da2226bca5532a6f564670e78bc340e93b515177b8741bd0a6f5aebd.
     How it applies: Label indications and limitations of use.

### The US Vascepa label says Vascepa is associated with an increased risk of atrial fibrillation or atrial flutter requiring hospitalization, and with an increased risk of bleeding.

- Category: Safety
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Adult patients named in the indications of the US label for Vascepa: adults with elevated triglycerides and established cardiovascular disease or diabetes plus other risk factors, and adults with severe hypertriglyceridemia.; Care setting: Prescription medicine; the label adds the medicine to statin treatment or to diet, as stated in the indications; Geography: United States (FDA label); Life stage: Adults; the label states adult patients; Follow-up: Not applicable (label text and a regulatory record)
- Limitations: Warnings as the label states them, in the label version dated 2026-03-23. The label gives event counts from one trial; this atlas does not repeat them and has not read the trial.
- Last checked: 2026-10-30
- Sources:
  1. Supports: Vascepa drug label (openFDA record, set id 9c1a2828-1583-4414-ab22-a60480e8e508) (Label, edition openFDA drug label record for the Amarin Pharma Inc. label of Vascepa, label effective 20260323, fetched 2026-10-30.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c1a2828-1583-4414-ab22-a60480e8e508>
     Locator: results\[0\].warnings\_and\_cautions\[0\]. Retrieved 2026-10-30T19:20:10Z. Source state: Current. Version fingerprint: 12fe4482da2226bca5532a6f564670e78bc340e93b515177b8741bd0a6f5aebd.
     How it applies: Label warnings and precautions, sections 5.1 and 5.3.

## Connected pages

- US label: indicated to lower severe hypertriglyceridemia and, with a statin, cardiovascular risk in adults with raised triglycerides: High triglycerides (`cardio:hypertriglyceridemia`) [a claim, not a settled fact; see claim `cardio:claim-icosapent-ethyl-label-indications` and its context]
- Filed under this front: Medicines (`cardio:front-medicines`)
- The US label says icosapent ethyl is an ethyl ester of an omega-3 fatty acid: Omega-3 fatty acid drugs (`cardio:omega-3-fatty-acid-drugs`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 1 registry product
- 4 registry trials

## Provenance

Content hash: 319e7ae642de075482d2d07a486fe7995f79a4494b07e88818f113640e3fa83c
Last substantive edit: 2026-10-30
Evidence last checked: 2026-10-30
